Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women

Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women

Blog Article

Sharath Gangadhara, Gianfilippo BertelliSouth West Wales Cancer Institute, Singleton Hospital, Swansea, UKAbstract: For more than Reptile 20 years, tamoxifen has been the gold standard for the adjuvant treatment of postmenopausal women with hormone-responsive early breast cancer.However, recent randomized trials have shown efficacy and tolerability benefits with the third-generation aromatase inhibitor anastrozole, resulting in an increased use of this agent in the adjuvant setting.Data on anastrozole’s long-term efficacy and tolerability are therefore of interest in clinical practice and will be reviewed here, especially in the Leather Journal light of the 100-month analysis of the ATAC (Anastrozole, Tamoxifen Alone or in Combination) trial.Keywords: anastrozole, aromatase inhibitors, breast cancer, adjuvant therapy .